- Home
- AS vs INSM Comparison
AS vs INSM Comparison
Compare AS & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AS
- INSM
- Stock Information
- Founded
- AS 1950
- INSM 1988
- Country
- AS Finland
- INSM United States
- Employees
- AS N/A
- INSM N/A
- Industry
- AS
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- AS
- INSM Health Care
- Exchange
- AS NYSE
- INSM Nasdaq
- Market Cap
- AS 21.2B
- INSM 19.1B
- IPO Year
- AS 2024
- INSM 2000
- Fundamental
- Price
- AS $39.41
- INSM $102.87
- Analyst Decision
- AS Strong Buy
- INSM Strong Buy
- Analyst Count
- AS 10
- INSM 17
- Target Price
- AS $39.00
- INSM $108.07
- AVG Volume (30 Days)
- AS 3.8M
- INSM 4.8M
- Earning Date
- AS 08-19-2025
- INSM 08-07-2025
- Dividend Yield
- AS N/A
- INSM N/A
- EPS Growth
- AS N/A
- INSM N/A
- EPS
- AS 0.38
- INSM N/A
- Revenue
- AS $5,463,300,000.00
- INSM $381,030,000.00
- Revenue This Year
- AS $20.48
- INSM $28.17
- Revenue Next Year
- AS $13.72
- INSM $120.09
- P/E Ratio
- AS $103.94
- INSM N/A
- Revenue Growth
- AS 20.27
- INSM 20.77
- 52 Week Low
- AS $10.11
- INSM $60.40
- 52 Week High
- AS $40.21
- INSM $106.83
- Technical
- Relative Strength Index (RSI)
- AS 63.14
- INSM 68.00
- Support Level
- AS $37.51
- INSM $95.27
- Resistance Level
- AS $39.96
- INSM $98.53
- Average True Range (ATR)
- AS 1.22
- INSM 2.83
- MACD
- AS -0.11
- INSM -0.87
- Stochastic Oscillator
- AS 77.90
- INSM 66.50
About AS AMER SPORTS INC
Amer Sports manages a diverse portfolio of 10 outdoor and action sports brands that collectively generated revenue of $5.2 billion in 2024. Although primarily owned by the Chinese conglomerate Anta Sports, Amer operates with a degree of autonomy. In its rapidly expanding China business, the company is subject to closer oversight, but it manages its operations outside of China with relative independence. In 2024, the firm generates 36% of its revenue from the Americas, 29% from Europe, the Middle East, and Africa, 25% from China, and 10% from Asia-Pacific, excluding China.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.